The Feasibility of a Motivational Enhancement Approach to Skin Cancer Prevention in a Sample of Young Adult Patients
The specific aims of this research are: Aim 1 - To describe the UV protection behaviors and beliefs of young adult patients in a dermatology clinic. Aim 2 - To examine whether or not the UV protection behaviors and beliefs of young adult dermatology patients are associated with age, gender, level of education, marital status, contact with skin cancer, time outdoors, skin type, the reason for their visit, and the date of data collection. Aim 3 - To test the efficacy of a motivational enhancement approach to UV protection counseling for young adult dermatology patients, as manifested by favorable changes in UV protection stages of change, UV protection self-efficacy, and UV protection attitudes.
NCT00705887 — Motivation
Status: Completed
http://inclinicaltrials.com/motivation/NCT00705887/
Evaluation of Protoporphyrin Formation in Non-Melanoma Skin Cancers After Topical Application of 5-Aminolevulinic Acid: A Pilot Study
RATIONALE: Studying samples of tumor tissue in the laboratory from patients with nonmelanoma skin cancer that has been treated with topical aminolevulinic acid may help doctors predict how patients will respond to photodynamic therapy. PURPOSE: This clinical trial is studying topical aminolevulinic acid in patients with nonmelanoma skin cancer.
NCT00663910 — Non-melanomatous Skin Cancer
Status: Terminated
http://inclinicaltrials.com/non-melanomatous-skin-cancer/NCT00663910/
A Single Arm, Single-centre, Open-label, Exploratory Trial of Recombinant Interleukin-21 Administered Subcutaneously for 4 Weeks as Neo-adjuvant Treatment Prior to Sentinel Lymph Node/Complete Lymph Node Dissection Followed by 8 Weeks of Adjuvant Treatment in Subjects With Stage III Malignant Melanoma
The trial is conducted in Europe. This trial aims for a comparison of the pathology in lymph nodes before and after the effect of recombinant interleukin-21 in patients with stage III melanoma
NCT00601861 — Cancer
Status: Terminated
http://inclinicaltrials.com/cancer/NCT00601861/
Regular Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients, Particularly in Xeroderma Pigmentosum and Basal Cell Nevus Syndrome
Study aim: To determine the effect of an intensified daily photoprotection over 24 months with an SPF30 sunscreen and an after sun-lotion both containing liposomal DNA repair enzymes in a population of patients at high-risk for skin cancer, including xeroderma pigmentosum (XP) and basal cell nevus syndrome.
NCT00555633 — Skin Cancer
Status: Completed
http://inclinicaltrials.com/skin-cancer/NCT00555633/
Quality of Life in Patients With Nonmelanoma Skin Cancer
The goal of this study is to learn more about the physical discomfort, sensory impairment, depression, anxiety, and interference with relationships, family, and work associated with NMSC via survey questions.
NCT00518037 — Nonmelanoma Skin Cancer
Status: Completed
http://inclinicaltrials.com/nonmelanoma-skin-cancer/NCT00518037/
A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer
Patients on immunosuppressive therapy, e.g. organ recipients, have a higher occurrence of AK than the untreated population. Keratotic lesions (i.e. AK lesions and warts) in this population is highly associated with development of SCC also with 10 times higher mortality rate because of SCC than expected. The risk of developing skin cancer, predominantly SCC and BCC, increases with graft survival time and the length of immunosuppressive treatment period. The higher risk of developing skin malignancy and more aggressive skin malignancies in this population, indicate the need for early removal of these pre-malignant lesions. In this study, two contralateral areas (5x10 cm2) with skin lesions within the patient will be compared. One area will receive Metvix PDT at defined intervals and the other will receive lesion specific treatment at the discretion of the investigator. The primary end-point will be the accumulated number of new lesions during the study and number of AK lesions that show complete response 3 months after baseline. Secondary endpoints will be number of BCC lesions that show complete response, number of recurrent lesions, assessment of cosmetic outcome and safety.
NCT00472459 — Squamous Cell Carcinoma
Status: Completed
http://inclinicaltrials.com/squamous-cell-carcinoma/NCT00472459/
A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PEG-interferon alfa-2a may interfere with the growth of tumor cells and slow the growth of skin cancer. Giving gefitinib together with PEG-interferon alfa-2a may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of PEG-interferon alfa-2a when given together with gefitinib and to see how well they work in treating patients with unresectable or metastatic skin cancer.
NCT00423397 — Non-melanomatous Skin Cancer
Status: Active, not recruiting
http://inclinicaltrials.com/non-melanomatous-skin-cancer/NCT00423397/
Diagnosis of Non-Melanoma Skin Cancer With Optical Coherence Tomography
We will do systematic and functional assessment of non-melanoma skin cancer including precancerous lesions by OCT imaging and other diagnostic methods. The systematic assessment will be comparison of clinical diagnosis, histopathology, OCT images, spectrophotometry and high frequency ultrasound of non-melanoma skin cancer Functional exploration of non-melanoma skin cancer is done with Doppler-OCT and polarization-sensitive-OCT.
NCT00390351 — Skin Neoplasms
Status: Recruiting
http://inclinicaltrials.com/skin-neoplasms/NCT00390351/
Efficacy of Web-Based Instruction on Skin Cancer Triage
RATIONALE: Computer-based continuing education courses may be effective in improving the skills of primary care doctors to identify skin cancer risk factors, perform skin cancer exams, and counsel patients. They may also improve the skills of primary care doctors to assess and counsel patients on their weight, diet, and physical activity. PURPOSE: This randomized clinical trial is studying how well computer-based continuing education courses work in improving doctors' ability to perform skin cancer or weight control exams and counseling during routine office visits.
NCT00295906 — Melanoma (Skin)
Status: Recruiting
http://inclinicaltrials.com/melanoma-skin/NCT00295906/
Phase 2b Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients (OTR)
This is a double blind, placebo controlled study of 52 patients who are at least one-year post-solid organ transplant. Subjects will receive either 12 months of DFMO or a placebo. The specific aims are to determine if DFMO at 500 mg daily will be well tolerated for 12 months and not affect organ transplant viability; will inhibit 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ornithine decarboxylase (ODC) in skin biopsies by approximately 50% for the 12 months of therapy; and will be able to decrease polyamine levels in skin biopsies for the 12 months of treatment.
NCT00204789 — Skin Neoplasms
Status: Completed
http://inclinicaltrials.com/skin-neoplasms/NCT00204789/